Results of late-breaking developments from the POSEIDON Phase III trial revealed improved overall survival with a limited course of five cycles of tremelimumab added to durvalumab plus platinum chemotherapy.
Friday
March
24
Top Stories
The Impact of Lymphovascular Space Invasion on Survival in Early Stage Low-Grade Endometrioid Endometrial Cancer
The present study was aimed to evaluate the impact of LVSI on survival in patients with early stage endometrioid endometrial cancer.
Aggrego Pulse - 3/23/23
On this week's episode of Aggrego Pulse, Dr Brian Van Tine, a professor of Sarcoma Oncology at Washington University in St.
Can Lymph Nodes Boost the Success of Cancer Immunotherapy?
New study findings from a clinical trial by researchers at UC San Francisco and Gladstone Institutes demonstrates that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes.
Response High for Bispecific Antibody Talquetamab in Multiple Myeloma
A substantial proportion of patients with heavily pretreated multiple myeloma responded to treatment with the bispecific antibody talquetamab, according to results of a phase I study published in
Trending
TV
Breast Cancer
Radio
Lung Cancer
Start your day with an email
that tells you what’s happening
and why it matters.
News
FDA Approvals
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->